The Cyber Problem Holding Back AI

Good morning, ! This week we’re diving into cybersecurity as AI’s biggest healthcare bottleneck, a close look into Estuary Bio, oncology pharma leaders market map, and this week’s most important news. 

Want to advertise in Healthcare 150? Check out our ad platform, here.

Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.

— The Healthcare150 Team

DATA DIVE

Hospital AI’s Next Bottleneck Is Cybersecurity

Hospital AI is moving from software that analyzes workflows to systems that can increasingly act inside them. The market is projected to expand from $37.0B in 2025 to $613.8B by 2034, but the next constraint may be less about model capability and more about how much authority hospitals are willing to delegate.

The tension is already visible. AI adoption reached 96% among hospitals with more than 400 beds, yet healthcare enters the agentic era with significant infrastructure exposure. 99% of hospitals operate devices containing known exploited vulnerabilities, while 85% manage vulnerable imaging systems, one of the areas where AI deployment is most advanced.

That changes the investment thesis. As AI moves into scheduling, communications, billing, clinical workflows, and administrative records, identity management, permissioning, auditability, and fallback infrastructure become part of the product, not compliance features added later.

For operators and investors, the winners may not be the platforms offering maximum autonomy. They may be those delivering the most automation hospitals can safely govern.

Read the Full Report HERE

You built the audience. Can you reach them?

You can have thousands of people following your work and still need an algorithm’s permission to reach them. Creators know the drill: you post, you pray, you check the numbers, you try again tomorrow.

A newsletter changes that relationship. On beehiiv, you can build a subscriber list you own, reach readers directly, and turn their attention into a sustainable business with subscriptions, sponsors, a global ad network, and more.

Get started for free.

COMPETITIVE LANDSCAPE SNAPSHOT

COMPANY OF THE WEEK

Estuary’s $103M Bet on Kidney Gene Therapy

Estuary Biotherapeutics is betting that kidney care can move beyond slowing disease to addressing its genetic cause. The company launched October 16 with $103 million in committed financing, including a $93 million Series A led by RA Capital.
Its focus is autosomal dominant polycystic kidney disease, where growing cysts damage the kidneys. Estuary is developing locally delivered gene therapies targeting PKD1 and PKD2, the genes responsible for most cases. Its first program is expected to enter the clinic in 2027, followed by a second in 2028.

Why it matters:​ This is a delivery bet as much as a biology bet. Reaching kidney cells could open a market for genetic medicines built around intervention rather than chronic disease management. But the investment case remains unproven: human safety and efficacy have not been established. The next milestone is whether targeted delivery can translate into durable clinical benefit with an acceptable safety profile. (More)

INTERESTING ARTICLES

"Quote"

Quote